

# Calcitonin Gene Related Peptide - Pipeline Review, H1 2020

<https://marketpublishers.com/r/CF0739DDC77BEN.html>

Date: March 2020

Pages: 81

Price: US\$ 3,500.00 (Single User License)

ID: CF0739DDC77BEN

## Abstracts

Calcitonin Gene Related Peptide - Pipeline Review, H1 2020

### SUMMARY

Calcitonin Gene Related Peptide (CGRP) pipeline Target constitutes close to 10 molecules. The latest report Calcitonin Gene Related Peptide - Pipeline Review, H1 2020, outlays comprehensive information on the Calcitonin Gene Related Peptide (CGRP) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Calcitonin Gene Related Peptide (CGRP) - Calcitonin gene related peptide (CGRP) is a member of the calcitonin family of peptides. It exists in two forms alpha-CGRP and beta-CGRP. CGRP is produced in both peripheral and central neurons. CGRP is derived mainly from the cell bodies of motor neurons when synthesized in the ventral horn of the spinal cord and contribute to the regeneration of nervous tissue after injury. CGRP is derived from dorsal root ganglion when synthesized in the dorsal horn of the spinal cord and linked to the transmission of pain. CGRP also plays an important role in cardiovascular homeostasis and nociception. The molecules developed by companies in Pre-Registration, Phase III, Preclinical and Discovery stages are 2, 1, 5 and 2 respectively. Report covers products from therapy areas Central Nervous System and Immunology which include indications Migraine, Cluster Headache Syndrome (Cluster Headache), Dental Pain (Toothache/Tooth Pain), Fibromyalgia (Fibromyalgia Syndrome), Inflammatory Pain, Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome), Osteoarthritis Pain, Pain, Psoriasis and Traumatic Pain.

Furthermore, this report also reviews key players involved in Calcitonin Gene Related Peptide (CGRP) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Calcitonin Gene Related Peptide (CGRP)

The report reviews Calcitonin Gene Related Peptide (CGRP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Calcitonin Gene Related Peptide (CGRP) targeted therapeutics and enlists all their major and minor projects

The report assesses Calcitonin Gene Related Peptide (CGRP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Calcitonin Gene Related Peptide (CGRP) targeted therapeutics

## REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Calcitonin Gene Related Peptide (CGRP)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Calcitonin Gene Related Peptide (CGRP) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Calcitonin Gene Related Peptide (CGRP) - Overview

Calcitonin Gene Related Peptide (CGRP) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Calcitonin Gene Related Peptide (CGRP) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Calcitonin Gene Related Peptide (CGRP) - Companies Involved in Therapeutics Development

AfaSci Inc

Aptarion biotech AG

Eli Lilly and Co

H. Lundbeck AS

Living Cell Technologies Ltd

Nepsone ehf

Pharmnovo AB

Serometrix LLC

Teva Pharmaceutical Industries Ltd

United Neuroscience Ltd

Calcitonin Gene Related Peptide (CGRP) - Drug Profiles

AFAP-3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eptinezumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fremanezumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

[Calcitonin Gene Related Peptide \(CGRP\) - Dormant Products](#)  
[Calcitonin Gene Related Peptide \(CGRP\) - Discontinued Products](#)  
[Calcitonin Gene Related Peptide \(CGRP\) - Product Development Milestones](#)  
[Featured News & Press Releases](#)  
[Appendix](#)  
[Methodology](#)  
[Coverage](#)  
[Secondary Research](#)  
[Primary Research](#)  
[Expert Panel Validation](#)  
[Contact Us](#)  
[Disclaimer](#)

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Indication, H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Pipeline by AfaSci Inc, H1 2020

Pipeline by Aptarion biotech AG, H1 2020

Pipeline by Eli Lilly and Co, H1 2020

Pipeline by H. Lundbeck AS, H1 2020

Pipeline by Living Cell Technologies Ltd, H1 2020

Pipeline by Nepsone ehf, H1 2020

Pipeline by Pharmnovo AB, H1 2020

Pipeline by Serometrix LLC, H1 2020

Pipeline by Teva Pharmaceutical Industries Ltd, H1 2020

Pipeline by United Neuroscience Ltd, H1 2020

Dormant Projects, H1 2020

Discontinued Products, H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

### COMPANIES MENTIONED

AfaSci Inc

Aptarion biotech AG

Eli Lilly and Co

H. Lundbeck AS

Living Cell Technologies Ltd

Nepsone ehf

Pharmnovo AB

Serometrix LLC

Teva Pharmaceutical Industries Ltd

United Neuroscience Ltd

## I would like to order

Product name: Calcitonin Gene Related Peptide - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/CF0739DDC77BEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CF0739DDC77BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970